Cardiology: 150 CME educational programs available now

Lipid/Metabolic

Experts' Corner: HDL & Cardiovascular Risk — The Year in Review

Feb 3, 2012 10:01 EST

Join Drs Rader and Blumenthal as they discuss the results of this year's major trials looking at reducing cardiovascular risk and raising HDL-C.

Lipid/Metabolic

ACS in Patients with Type 2 Diabetes: Exploring New Pathways to Reduce Cardiovascular Risk

Jan 31, 2012 11:00 EST

Join Dr Jorge Plutzky as he discusses the potential for PPAR agonists in reducing cardiovascular risk in patients with type 2 diabetes.

Lipid/Metabolic

Is CETP Inhibition the Answer to Residual Risk? A Global Perspective

Jan 24, 2012 14:22 EST

Join Drs. Rosenson, Lüscher, and Deanfield as they discuss the potential clinical impact of AIM-HIGH and the latest CETP-inhibitor clinical trials from a global perspective.

Lipid/Metabolic

Highlight on CETP: Role in Lipid Metabolism and Homeostasis

Dec 23, 2011 09:45 EST

Join Dr. Rader as he discusses whether a change in HDL cholesterol level reflects proper HDL particle function or therapeutic success.

Lipid/Metabolic

Addressing Residual Risk in the ACS Patient: Knowing the Numbers

Dec 21, 2011 08:21 EST

Join Drs. Chapman, Gotto, and Kastelein as they discuss the results of AIM-HIGH and the latest CETP-inhibitor clinical trials in HDL-targeted residual cardiovascular risk reduction.

Lipid/Metabolic

Late-Breaking Developments in the Treatment of Dyslipidemia: Are All Omega-3 Fatty Acids the Same?

2 COMMENTS - Dec 20, 2011 14:17 EST

Join our experts Drs. Miller, Schaefer, Jacobson, and Bays as they discuss current and future management of the patient with hyperlipidemia.

Lipid/Metabolic

HDL Quality: Is It a Better Target Than HDL-C?

Dec 20, 2011 11:21 EST

Join Dr. Nicholls as he discusses the clinical significance of HDL-C for residual cardiovascular risk and whether HDL functionality would be a better predictor of therapeutic success. And DISCUSS this topic with Dr. Nicholls on Medscape Discuss.

Lipid/Metabolic

Statin Therapy Case Challenge: Lipid Treatment Strategies in Patients With HIV

Dec 14, 2011 14:47 EST

Join Drs. Underberg and Waters as they discuss dyslipidemia in patients with HIV and the appropriate selection of statin therapy to avoid drug-drug interactions.

Lipid/Metabolic

HDL-C and AIM-HIGH: Does Increasing HDL-C Reduce Cardiovascular Risk?

Dec 9, 2011 14:12 EST

Join Drs. Davidson, Toth, and Boden as they discuss the results of the AIM-HIGH trial and its implications on the treatment of low HDL-C with currently available agents.

Lipid/Metabolic

HDL and CHD: New Mechanisms Targeting Risk

1 COMMENT - Dec 7, 2011 10:15 EST

Join Drs. Eckel, Ridker, and Cannon for a panel discussion on the relationship among LDL-C, low HDL-C, and therapies in development targeting residual CV risk.

Lipid/Metabolic

Statin Intolerance in the Elderly: Solutions for Complex Cases

11 COMMENTS - Nov 28, 2011 16:20 EST

Join Drs. Fuster, Barter, and Toth as they discuss the challenges of identifying statin intolerance in elderly patients and how to manage it effectively.

Lipid/Metabolic

New Directions in the Treatment of Mixed Dyslipidemia and Residual Risk

Nov 28, 2011 09:34 EST

Join our experts Drs. Ballantyne, Schaefer, Miller, and Bays as they discuss perspectives from AHA 2011 meeting on improving the standard of care for patients with dyslipidemia.

Lipid/Metabolic

Dilemmas in Diabetes and Cardiovascular Disease: Positioning PPAR Agonists to Address the Big Picture

Nov 17, 2011 15:00 EST

Join Drs. Betteridge and Charbonnel as they discuss PPAR agonists in development and their potential in cardiovascular risk reduction.

Lipid/Metabolic

Polypharmacy and Statin Selection: Reducing the Potential for Drug-Drug Interactions

1 COMMENT - Nov 7, 2011 13:14 EST

Join Drs. Foody and Dall as they discuss managing statin intolerance, drug-drug interactions, and statin therapy selection in patients with dyslipidemia.

Lipid/Metabolic

HDL: The Next Frontier in Reducing Atherosclerosis and Cardiovascular Risk in Type 2 Diabetes?

2 COMMENTS - Nov 1, 2011 09:00 EDT

Join Drs. Bruckert, von Eckardstein, and Stalenhoef as they discuss the latest data on reducing residual cardiovascular risk in patients with type 2 diabetes.

Lipid/Metabolic

Residual Risk Management and HDL: Clinician Survey

2 COMMENTS - Oct 21, 2011 09:30 EDT

There is growing evidence that targeting HDL may reduce residual CV risk. You are invited to participate in this educational survey to gauge physician practice patterns and knowledge of dyslipidemia.

Lipid/Metabolic

HDL Targeting Therapies: Updates from the European Society of Cardiology

Sep 28, 2011 12:00 EDT

Join Drs. Barter, Fayad, Kastelein, and Nicholls as they discuss HDL functionality and the clinical implications of HDL modulation.

Lipid/Metabolic

Can Targeting CETP Halt Atherosclerosis Progression? Examining the Evidence

8 COMMENTS - Sep 28, 2011 09:00 EDT

Join Drs. Tardif and Fayad for a discussion of the latest clinical trials in HDL-C-modifying therapy.

Lipid/Metabolic

Pathophysiology of Severe Familial Hypercholesterolemia: The Role of Apo B

1 COMMENT - Sep 26, 2011 08:24 EDT

Join Drs. Ballantyne, Tsimikas, and Bruckert for a discussion on the pathophysiology and management of severe FH.

Lipid/Metabolic

HDL-C in the Spotlight: Modulating CETP to Reduce Cardiovascular Risk

Sep 19, 2011 09:17 EDT

Join Drs. Chapman, Brewer, and Deanfield for a discussion on low HDL-C and the potential role CETP inhibitors may play in reducing residual cardiovascular risk.

Lipid/Metabolic

Residual Cardiovascular Risk Management: HDL-C in Focus

34 COMMENTS - Sep 6, 2011 11:03 EDT

This survey is being conducted to gauge physician-practice patterns in the management of patients with dyslipidemia and low HDL-C.

Lipid/Metabolic

First Response from the European Society of Cardiology (ESC): Emerging Therapies Targeting HDL

Sep 1, 2011 10:23 EDT

Interpret emerging clinical data concerning the safety and clinical implications of cholesteryl ester transfer protein inhibition and the future implications of trials on HDL modulation in reduction of cardiovascular risk.

Lipid/Metabolic

Novel, Targeted, and Appropriate PPAR Therapy: New Paradigms for Residual Risk Management

1 COMMENT - Aug 26, 2011 11:23 EDT

What do clinical trials tell us about the use of PPARs for residual risk management in type 2 diabetes and cardiovascular disease?

Lipid/Metabolic

Risk Assessment and Management of CVD in Patients With CKD

Aug 24, 2011 09:48 EDT

Join Drs. McCullough, Singh, and Griffith as they review the management of CVD in patients with CKD from 3 different clinical perspectives.

Lipid/Metabolic

Residual Risk Management: Case-Based Assessment

4 COMMENTS - Aug 22, 2011 16:00 EDT

Despite receiving LDL-C-lowering therapy, residual cardiovascular risk remains significant in patients with dyslipidemia. You are invited to participate in this educational survey to gauge physician-practice patterns in the management of dyslipidemia.